Health
Pfizer’s Hympavzi Wins FDA Approval to Treat Hemophilia
Hympavzi is approved for patients aged 12 and older with hemophilia A or B who haven’t developed antibodies to previous treatment.
Photographer: Sophie Park/BloombergThis article is for subscribers only.
Pfizer Inc.’s Hympavzi won US approval to treat hemophilia, a potentially deadly genetic disorder that prevents blood from clotting properly.
The once-weekly injection prevents or reduces the frequency of bleeding episodes that can do long-term damage to patients, Pfizer said in a statement. The drug, the first in a new class of medicines for the condition, costs $795,600 annually, the company said.